Longitudinal trends in prostate cancer incidence, mortality, and survival of patients from two Shanghai city districts: a retrospective population-based cohort study, 2000–2009

BMC Public Health

Biao Xu⁴  Hong Yuan²  Haiju Deng³  Jianyu Rao¹  Qi Zhao⁴  Yi Hu⁴ 

[1] David Geffen School of Medicine and Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA, USA;Center for Disease Prevention and Control, Jiading District, Shanghai, China;Center for Disease Prevention and Control, Putuo District, Shanghai, China;Department of Epidemiology, School of Public Health, Key Laboratory of Public Health Safety, Ministry of Education, Fudan University, Shanghai 200032, China

关键词: China;    Survival;    Mortality;    Incidence;    Prostate cancer;   

Others  :  1131565
DOI  :  10.1186/1471-2458-14-356

 received in 2013-09-16, accepted in 2014-04-09,  发布年份 2014

【 摘 要 】

Background

Prostate cancer is the fifth most common cancer affecting men of all ages in China, but robust surveillance data on its occurrence and outcome is lacking. The specific objective of this retrospective study was to analyze the longitudinal trends of prostate cancer incidence, mortality, and survival in Shanghai from 2000 to 2009.

Methods

A retrospective population-based cohort study was performed using data from a central district (Putuo) and a suburban district (Jiading) of Shanghai. Records of all prostate cancer cases reported to the Shanghai Cancer Registry from 2000 to 2009 for the two districts were reviewed. Prostate cancer outcomes were ascertained by matching cases with individual mortality data (up to 2010) from the National Death Register. The Cox proportional hazards model was used to analyze factors associated with prostate cancer survival.

Results

A total of 1022 prostate cancer cases were diagnosed from 2000 to 2009. The average age of patients was 75 years. A rapid increase in incidence occurred during the study period. Compared with the year 2000, 2009 incidence was 3.28 times higher in Putuo and 5.33 times higher in Jiading. Prostate cancer mortality declined from 4.45 per 10⁵ individuals per year in 2000 to 1.94 per 10⁵ in 2009 in Putuo and from 5.45 per 10⁵ to 3.5 per 10⁵ in Jiading during the same period. One-year and 5-year prostate cancer survival rates were 95% and 56% in Putuo, and 88% and 51% in Jiading, respectively. Staging of disease, Karnofsky Performance Scale Index, and selection of chemotherapy were three independent factors influencing the survival of prostate cancer patients.

Conclusions

The prostate cancer incidence increased rapidly from 2000 to 2009, and prostate cancer survival rates decreased in urban and suburban Chinese populations. Early detection and prompt prostate cancer treatment is important for improving health and for increasing survival rates of the Shanghai male population.

【 授权许可】

   
2014 Hu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: GLOBOCAN 2008 v2.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr webcite [accessed 23/02/2014]
• [2]Hsing AW, Devesa SS, Jin F, Gao YT: Rising incidence of prostate cancer in Shanghai, China. Cancer Epidemiol Biomarkers Prev 1998, 7(1):83-84.
• [3]Ying-Xiu Z, Shu-Rong W: Secular trends in body mass index and the prevalence of overweight and obesity among children and adolescents in Shandong, China, from 1985 to 2010. J Public Health (Oxf) 2012, 34(1):131-137.
• [4]ᅟ: American Urological Association releases guidelines for the management of localized prostate cancer. Am Fam Physician 1996, 53(8):2751-2752.
• [5]Ladjevardi S, Sandblom G, Berglund A, Varenhorst E: Tumour grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer. Eur Urol 2010, 57(4):631-638.
• [6]Abdollah F, Gandaglia G, Thuret R, Schmitges J, Tian Z, Jeldres C, Passoni NM, Briganti A, Shariat SF, Perrotte P, Montorsi F, Karakiewicz PI, Sun M: Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. Cancer Epidemiol 2013, 37(3):219-225.
• [7]Nygard M, Aagnes B, Bray F, Moller B, Mork J: Population-based evidence of increased survival in human papillomavirus-related head and neck cancer. Eur J Cancer 2012, 48(9):1341-1346.
• [8]Zeigler-Johnson CM, Rennert H, Mittal RD, Jalloh M, Sachdeva R, Malkowicz SB, Mandhani A, Mittal B, Gueye SM, Rebbeck TR: Evaluation of prostate cancer characteristics in four populations worldwide. Can J Urol 2008, 15(3):4056-4064.
• [9]Hemminki K: Familial risk and familial survival in prostate cancer. World J Urol 2012, 30(2):143-148.
• [10]Brandt A, Sundquist J, Hemminki K: Risk for incident and fatal prostate cancer in men with a family history of any incident and fatal cancer. Ann Oncol 2012, 23(1):251-256.
• [11]Huang M, Narita S, Numakura K, Tsuruta H, Saito M, Inoue T, Horikawa Y, Tsuchiya N, Habuchi T: A high-fat diet enhances proliferation of prostate cancer cells and activates MCP-1/CCR2 signaling. Prostate 2012, 72(16):1779-1788.
• [12]Marshall JR: Diet and prostate cancer prevention. World J Urol 2012, 30(2):157-165.
• [13]Lughezzani G: The relationship between obesity and prostate cancer: from genetics to disease treatment and prevention. BMC Med 2012, 10:109. BioMed Central Full Text
• [14]Fowke JH, Motley SS, Concepcion RS, Penson DF, Barocas DA: Obesity, body composition, and prostate cancer. BMC Cancer 2012, 12:23. BioMed Central Full Text
• [15]Wang H, Wang J, Liu MM, Wang D, Liu YQ, Zhao Y, Huang MM, Liu Y, Sun J, Dong GH: Epidemiology of general obesity, abdominal obesity and related risk factors in urban adults from 33 communities of Northeast China: the CHPSNE study. BMC Public Health 2012, 12:967. BioMed Central Full Text
• [16]Wang D, Zheng W, Wang SM, Wang JB, Wei WQ, Liang H, Qiao YL, Boffetta P: Estimation of cancer incidence and mortality attributable to overweight, obesity, and physical inactivity in China. Nutr Cancer 2012, 64(1):48-56.
• [17]Shen J, Goyal A, Sperling L: The emerging epidemic of obesity, diabetes, and the metabolic syndrome in China. Cardiol Res Pract 2012, 2012:178675.
• [18]Li X, Xu J, Yao H, Guo Y, Chen M, Lu W: Obesity and overweight prevalence and its association with undiagnosed hypertension in Shanghai population, China: a cross-sectional population-based survey. Front Med 2012, 6(3):322-328.
• [19]Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Paez A, Maattanen L, Bangma CH, Aus G, Carlsson S, Villers A, Rebillard X, van der Kwast T, Kujala PM, Blijenberg BG, Stenman UH, Huber A, Taari K, Hakama M, Moss SM, de Koning HJ, Auvinen A: Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012, 366(11):981-990.
• [20]Sarma AV, Schottenfeld D: Prostate cancer incidence, mortality, and survival trends in the United States: 1981–2001. Semin Urol Oncol 2002, 20(1):3-9.
• [21]Abdollah F, Sun M, Schmitges J, Thuret R, Bianchi M, Shariat SF, Briganti A, Jeldres C, Perrotte P, Montorsi F, Karakiewicz PI: Survival benefit of radical prostatectomy in patients with localized prostate cancer: estimations of the number needed to treat according to tumor and patient characteristics. J Urol 2012, 188(1):73-83.
• [22]Vickers A, Bennette C, Steineck G, Adami HO, Johansson JE, Bill-Axelson A, Palmgren J, Garmo H, Holmberg L: Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial. Eur Urol 2012, 62(2):204-209.
• [23]Hennenfent BR: Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer. Br J Urol 1998, 82(1):166.